Chronopharmacology of the fisetin/glimepiride combination in the amelioration of diabetic retinopathy in rat model

Arumugam Madeswaran, Velumani Mathivanan, DOI: 10.46793/BiolNyss.16.1.13M

Abstract


Diabetic retinopathy is a complication of diabetes caused by high blood sugar levels that damage the back of the eye (retina), potentially leading to blindness. The aim of the present study is to investigate the efficacy of fisetin and glimepiride combination in the management of diabetic retinopathy through a chronopharmacological approach. For the in vivo chronopharmacological study, male Wistar rats were divided into six groups, each comprising six animals. The treatment groups received 100 mg/kg of fisetin and glimepiride at different circadian time points (8:00 h, 14:00 h, and 20:00 h) for 28 consecutive days. The blood glucose levels of the animals were monitored during the treatment. On day 29, rats were euthanized, and biochemical and histopathological analyses were performed using a section of the rat eye. The group that received fisetin and glimepiride at 20:00 h showed a significant reduction in the glucose levels (9.46±7.86 mmol/L, p<0.05), decreased cholesterol and triglyceride levels, as well as lower malondialdehyde level compared to other treated groups and the positive control group. It can be concluded that the administration of glimepiride with fisetin at 20:00 h was more effective than other groups and that this administration time will reduce diabetic retinopathy complications. However, further studies are needed to elucidate these effects before clinical translation for managing diabetic retinopathy.


Keywords


chronopharmacology, diabetic retinopathy, flavonoids, streptozotocin

Full Text:

PDF

References


Adekemi, F.E., Folake, J.K. & Omowumi, F.P. (2024). Antidiabetic effects of aqueous leaf extract of Vernonia amygdalina on serum liver markers in streptozotocin-induced diabetic albino rats: a new data to support its anti-diabetic effect. Clinical Phytoscience, 10, 13-18.

Alzand, K.I. & Mohamed, M.A. (2012). Flavonoids: chemistry, biochemistry, and antioxidant activity. Journal of Pharmacy Research, 5(40134012), 37-42.

Ansari, P., Tabasumma, N., Snigdha, N.N., Siam, N.H., Panduru, R.V.N.R.S. Azam, S. & Hannan, J.M.A. (2022). Abdel-Wahab, Y.H.A. Diabetic retinopathy: An overview on mechanisms, pathophysiology and pharmacotherapy. Diabetology, 3,159-175.

Brodowska, K.M. (2017). Natural flavonoids: classification, potential role, and application of flavonoid analogues. European Journal of Biological Research, 7(2), 108-123.

Chait, A. & den Hartigh, L.J. (2020). Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Frontiers in Cardiovascular Medicine, 7, 22-28.

Cruz, P.L., Moraes-Silva, I.C., Ribeiro, A.A., Machi, J.F., de Melo, M.D.T., Santos, F.D., da Silva, M.B., Strunz, C.M.C., Caldini, E.G. & Irigoyen, M.C. (2021). Nicotinamide attenuates streptozotocin-induced diabetes complications and increases survival rate in rats: role of autonomic nervous system. BMC Endocrine Disorders, 21, 133-138.

Dobrek, L. (2021). Chronopharmacology in therapeutic drug monitoring-dependencies between the rhythmics of pharmacokinetic processes and drug concentration in blood. Pharmaceutics, 13(11), 1915-1923.

Du, Y., Veenstra, A., Palczewski, K. & Kern, T.S. (2013). Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proceedings of the National Academy of Sciences USA, 110(41), 16586-16591.

Duh, E.J., Sun, J.K. & Stitt, A.W. (2017). Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight, 2(14), e93751-e93757.

Ellis, M.P., Lent-Schochet, D., Lo, T. & Yiu, G. (2019). Emerging concepts in the treatment of diabetic retinopathy. Current Diabetes Reports, 19, 137-144.

Erkekoglu, P. & Baydar, T. (2012). Chronopharmacodynamics of drugs in toxicological aspects: A short review for clinical pharmacists and pharmacy practitioners. Journal of Research in Pharmacy Practice, 1(2), 41-47.

Ghasemi, A., Khalifi, S. & Jedi, S. (2014). Streptozotocin-nicotinamide-induced rat model of type 2 diabetes. Acta Physiologica Hungarica, 101, 408-420.

Kennard, M.R., Daniels, G.L.F., Roberts, A.G., White, E.R.P., Nandi, M. & King, A.J.F. (2021). The use of mice in diabetes research: The impact of experimental protocols. Diabetic Medicine, 38: e14705-e14711.

Kharoubi, O., Slimani, M. & Aoues, A. (2011). Neuroprotective effect of wormwood against lead exposure. Journal of Emergencies, Trauma, and Shock, 4(1), 82-88.

Kim, S. & Lee, H.J. (2020). Sleep and circadian rhythm disturbances in eating disorders. Chronobiology in Medicine, 2, 141-147.

Lee, H.J. (2022). Unraveling the significance of circadian rhythms for health. Chronobiology in Medicine, 4, 93-94.

Naderi, A., Zahed, R., Aghajanpour, L., Amoli, F.A. & Lashay, A. (2019). Long term features of diabetic retinopathy in streptozotocin-induced diabetic Wistar rats. Experimental Eye Research, 184, 213-220,

Oraebosi, M.I., Olurishe, T.O., Anafi, S.B. & Bisalla, M. (2021). Chronopharmacology of the alpha-lipoic acid/nifedipine/glimepiride combination in the amelioration of retinopathy in rats. Chronobiology International, 38(3), 443-450.

Parasuraman, S., Raveendran, R. & Kesavan, R. (2010). Blood sample collection in small laboratory animals. Journal of Pharmacology and Pharmacotherapeutics, 1(2), 87-93.

Perez-Vizcaino, F. & Fraga, C.G. (2018). Research trends in flavonoids and health. Archives of Biochemistry and Biophysics, 646, 107-112.

Prasath, G.S., Pillai, S.I. & Subramanian, S.P. (2014). Fisetin improves glucose homeostasis through the inhibition of gluconeogenic enzymes in hepatic tissues of streptozotocin induced diabetic rats. European Journal of Pharmacology, 740, 248-254.

Prasath, G.S. & Subramanian, S.P. (2011). Modulatory effects of fisetin, a bioflavonoid, on hyperglycemia by attenuating the key enzymes of carbohydrate metabolism in hepatic and renal tissues in streptozotocin-induced diabetic rats. European Journal of Pharmacology, 668(3), 492-496.

Reed, J., Bain, S. & Kanamarlapudi, V. (2021). A review of current trends with Type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives. Diabetes, Metabolic Syndrome and Obesity, 14, 3567-3602.

Roy, A., Khan, A., Ahmad, I., Alghamdi, S., Rajab, B.S., Babalghith, A.O., Alshahrani, M.Y., Islam, S. & Islam, M.R. (2022). Flavonoids a bioactive compound from medicinal plants and its therapeutic applications. BioMed Research International, 2022, 5445291-5445295.

Tajammal, A., Siddiqa, A. & Irfan, A. (2022). Antioxidant, molecular docking and computational investigation of new flavonoids. Journal of Molecular Structure, 1254: 132189.

Taylor, S.I., Blau, J.E. & Rother, K.I. (2015). SGLT2 inhibitors may predispose to ketoacidosis. The Journal of Clinical Endocrinology & Metabolism, 100(8), 2849-2852.

Wael, M.A., Noha, E.I., Amgad, K.H., Wagdy, K.B., Hassan, A., Hamdy, A.T. & Kawkab, A.A. (2023). The hepato- and neuroprotective effect of gold Casuarina equisetifolia bark nano-extract against Chlorpyrifos-induced toxicity in rats. Journal of Genetic Engineering and Biotechnology, 21(1), 158-162.

Whitehead, M., Wickremasinghe, S., Osborne, A., Van Wijngaarden, P. & Martin, K.R. (2018). Diabetic retinopathy: A complex pathophysiology requiring novel therapeutic strategies. Expert Opinion on Biological Therapy, 18, 1257-1270.

Zhong, Q. & Kowluru, R.A. (2011). Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes, 60(4), 1304-1313.


Refbacks

  • There are currently no refbacks.